Volkova M A, Kaletin G I, Pirogova N A
Ter Arkh. 1993;65(7):18-23.
78 previously untreated patients with acute non-lymphoblastic leukemia (ANLL) were assigned to cytosar-anthracyclines therapeutic programs: 29 (group I) received daunorubicin and AraC, 18 (group II) aclacinomycin A and AraC, 12 (group III) the scheme 3 + 7 with 12 mg/m2 novantron instead of daunorubicin, 19 (group IV) the scheme 3 + 7 with 12 mg/m2 idarubicin and cytosar. Groups I-III comprised both prognostically favorable and unfavorable ANLL variants, group 4 patients had for the most part unfavorable prognosis (MO-M3). A mean age of the patients was 41-42. Complete remissions were observed in 17 (58.6%), 9 (50%), 10 (83.3%), 11 (57.9%) patients of groups I, II, III and IV, respectively. An initial course of the treatment produced complete remissions in 65%, 33%, 80% and 90.9% of them, respectively. A mean duration of cytostatic leukothrombocytopenia was the longest in groups III and IV (16-22 days). Nonhematological toxicity occurred in the form of enteropathy and hepatitis. During the remission induction and consolidation 76% of the deaths were caused by infection and hemorrhagic diathesis. The median remission lasted 17.5, 13.5 and 5 months in groups I, II and III, respectively, and was not reached in group IV because of continuing remission in 50% of the patients by the end of the follow-up period (14 months). A 2-year survival rate was observed in 25% (group I), 11% (group II), 30% (group III) and 40% (group IV).
78例既往未接受过治疗的急性非淋巴细胞白血病（ANLL）患者被分配到阿糖胞苷 - 蒽环类药物治疗方案中：29例（I组）接受柔红霉素和阿糖胞苷，18例（II组）接受阿克拉霉素A和阿糖胞苷，12例（III组）采用3 + 7方案，用12mg/m²去甲氧柔红霉素代替柔红霉素，19例（IV组）采用3 + 7方案，用12mg/m²伊达比星和阿糖胞苷。I - III组包括预后良好和不良的ANLL变异型，IV组患者大多预后不良（MO - M3）。患者的平均年龄为41 - 42岁。I、II、III和IV组分别有17例（58.6%）、9例（50%）、10例（83.3%）、11例（57.9%）患者达到完全缓解。治疗的初始疗程分别使其中65%、33%、80%和90.9%的患者达到完全缓解。细胞毒性导致的白细胞和血小板减少的平均持续时间在III组和IV组最长（16 - 22天）。非血液学毒性表现为肠病和肝炎。在缓解诱导和巩固期间，76%的死亡是由感染和出血素质引起的。I、II和III组的中位缓解期分别持续17.5、13.5和5个月，IV组未达到中位缓解期，因为到随访期结束（14个月）时50%的患者仍持续缓解。I组、II组、III组和IV组的2年生存率分别为25%、11%、30%和40%。
